Acetylation controls Notch3 stability and function in T-cell leukemia

Oncogene

Volumn 31, Issue 33, 2012, Pages 3807-3817

  Palermo, R ^a   Checquolo, S ^a   Giovenco, A ^a   Grazioli, P ^b   Kumar, V ^b   Campese, A F ^b   Giorgi, A ^a   Napolitano, M ^b,c   Canettieri, G ^b   Ferrara, G ^b   Schinina M E ^a   Maroder, M ^a   Frati, L ^b,d   Gulino, A ^b,d   Vacca, A ^a   Screpanti, I ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

acetylation; leukemia; Notch3; T ALL

Indexed keywords

HISTONE DEACETYLASE 1; LYSINE; NOTCH3 RECEPTOR; PROTEIN P300; TRICHOSTATIN A;

ACETYLATION; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; DRUG EFFECT; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; TRANSCRIPTION REGULATION; UBIQUITINATION;

ACETYLATION; ANIMALS; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, T-CELL; LYMPHOCYTE ACTIVATION; MICE; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, NOTCH; T-LYMPHOCYTES; UBIQUITINATION;

MUS; MUS MUSCULUS;

EID: 84865202947     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.533     Document Type: Article

References (41)

1. Aifantis I, Raetz E, Buonamici S. (2008). Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 8: 380-390. (Pubitemid 351595220)
2. Anastasi E, Campese AF, Bellavia D, Bulotta A, Balestri A, Pascucci M et al. (2003). Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol 171: 4504-4511. (Pubitemid 37310565)
3. Barbarulo A, Grazioli P, Campese AF, Bellavia D, Di Mario G, Pelullo M et al. (2011). Notch3 and canonical NF-{kappa}B signaling pathways cooperatively regulate Foxp3 transcription. J Immunol 186: 6199-6206.
4. Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, Balestri A et al. (2000). Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 19: 3337-3348. (Pubitemid 30428211)
5. Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, Cazzaniga G et al. (2002). Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci USA 99: 3788-3793. (Pubitemid 34252184)
6. Bellavia D, Mecarozzi M, Campese AF, Grazioli P, Talora C, Frati L et al. (2007). Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. EMBO J 26: 1670-1680. (Pubitemid 46480945)
7. Beverly LJ, Felsher DW, Capobianco AJ. (2005). Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res 65: 7159-7168. (Pubitemid 41161246)
8. Bolden JE, Peart MJ, Johnstone RW. (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. (Pubitemid 44348499)
9. Bots Jr M. (2009). Rational combinations using HDAC inhibitors. Clin Cancer Res 15: 3970-3977.
10. Buchwald M, Kramer OH, Heinzel T. (2009). HDACi-targets beyond chromatin. Cancer Lett 280: 160-167.
11. Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P et al. (2010). Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol 12: 132-142.
12. Checquolo S, Palermo R, Cialfi S, Ferrara G, Oliviero C, Talora C et al. (2010). Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia. Oncogene 29: 1463-1474.
13. Clappier E, Collette S, Grardel N, Girard S, Suarez L, Brunie G et al. (2010). NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 24: 2023-2031.
14. Felli MP, Vacca A, Calce A, Bellavia D, Campese AF, Grillo R et al. (2005). PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene 24: 992-1000. (Pubitemid 40313876)
15. Galbiati L, Mendoza-Maldonado R, Gutierrez MI, Giacca M. (2005). Regulation of E2F-1 after DNA damage by p300-mediated acetylation and ubiquitination. Cell Cycle 4: 930-939. (Pubitemid 41359760)
16. Grozinger CM, Schreiber SL. (2002). Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9: 3-16. (Pubitemid 34155860)
17. Guarani V, Deflorian G, Franco CA, Kruger M, Phng LK, Bentley K et al. (2011). Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 473: 234-238.
18. Hernandez-Hernandez A, Ray P, Litos G, Ciro M, Ottolenghi S, Beug H et al. (2006). Acetylation and MAPK phosphorylation cooperate to regulate the degradation of active GATA-1. EMBO J 25: 3264-3274. (Pubitemid 44141785)
19. Ianari A, Gallo R, Palma M, Alesse E, Gulino A. (2004). Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J Biol Chem 279: 30830-30835. (Pubitemid 38938017)
20. Insinga A, Minucci S, Pelicci PG. (2005a). Mechanisms of selective anticancer action of histone deacetylase inhibitors. Cell Cycle 4: 741-743. (Pubitemid 41353820)
21. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. (2005b). Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76. (Pubitemid 40215840)
22. Kim MY, Ann EJ, Kim JY, Mo JS, Park JH, Kim SY et al. (2007). Tip60 histone acetyltransferase acts as a negative regulator of Notch1 signaling by means of acetylation.Mol Cell Biol 27: 6506-6519.
23. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G et al. (2002). Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21: 2672-2681. (Pubitemid 34619383)
24. Leduc C, Claverie P, Eymin B, Col E, Khochbin S, Brambilla E et al. (2006). p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation. Oncogene 25: 4147-4154. (Pubitemid 44079448)
25. Mateo F, Vidal-Laliena M, Canela N, Busino L, Martinez-Balbas MA, Pagano M et al. (2009). Degradation of cyclin A is regulated by acetylation. Oncogene 28: 2654-2666.
26. Mercurio C, Minucci S, Pelicci PG. (2010). Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62: 18-34.
27. Minucci S, Pelicci PG. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51. (Pubitemid 43054973)
28. Mulligan P, Yang F, Di Stefano L, Ji JY, Ouyang J, Nishikawa JL et al. (2011). A SIRT1-LSD1 corepressor complex regulates notch target gene expression and development. Mol Cell 42: 689-699.
29. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. (2005). Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11: 77-84. (Pubitemid 40215841)
30. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J et al. (1996). Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 183: 2283-2291. (Pubitemid 26158919)
31. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L et al.(2003). Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 5: 552-558. (Pubitemid 36781090)
32. Piekarz RL, Sackett DL, Bates SE. (2007). Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 13: 30-39.
33. Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, Howard BH et al. (1997). Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1: 35-45. (Pubitemid 127376391)
34. Screpanti I, Bellavia D, Campese AF, Frati L, Gulino A. (2003). Notch, a unifying target in T-cell acute lymphoblastic leukemia? Trends Mol Med 9: 30-35. (Pubitemid 36139253)
35. Stockhausen MT, Sjolund J, Manetopoulos C, Axelson H. (2005). Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer 92: 751-759. (Pubitemid 40460614)
36. Talora C, Campese AF, Bellavia D, Pascucci M, Checquolo S, Groppioni M et al. (2003). Pre-TCR-triggered ERK signallingdependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. EMBO Rep 4: 1067-1072. (Pubitemid 37527425)
37. Talora C, Cialfi S, Oliviero C, Palermo R, Pascucci M, Frati L et al. (2006). Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development and leukemogenesis. Blood 107: 3313-3320.
38. Talora C, Sgroi DC, Crum CP, Dotto GP. (2002). Specific downmodulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 16: 2252-2263. (Pubitemid 35013088)
39. Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P et al. (2007). HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 39: 1500-1509. (Pubitemid 47031039)
40. Vacca A, Felli MP, Palermo R, Di Mario G, Calce A, Di Giovine M et al. (2006). Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. EMBO J 25: 1000-1008. (Pubitemid 43372114)
41. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD et al. (2010). Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17: 427-442.